Pfizer Reports real-world evidence Data for Bevacizumab in Prostate cancer

Pfizer today announced real-world evidence results for bevacizumab in patients with prostate cancer. The study demonstrated that bevacizumab reduces exacerbation rates compared to standard of care or placebo. These results provide important insights into the treatment of prostate cancer and support the continued development of bevacizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.